Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 12/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
| ▸ | SKP1 | P63208 | 1/20 | 0.40 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015195 | 0.82 | CKS1B (0.46) | PIK3CAGPR119CKS1BSKP1SKP2 | |
| SCHEMBL12937468 | 0.82 | MAPT (0.52) | NPC1PIK3CAGPR119 | |
| SCHEMBL12804909 | 0.82 | PIK3CA (0.48) | PIK3CAGPR119CKS1BSKP1SKP2 | |
| SCHEMBL12937669 | 0.81 | MAPT (0.48) | NPC1RAB9ACKS1BSKP1SKP2 | |
| SCHEMBL3768360 | 0.80 | NPC1 (0.70) | NPC1RAB9AFAAHCKS1BSKP1 | |
| SCHEMBL2015994 | 0.79 | RARA (0.50) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL8512735 | 0.78 | GPR119 (0.48) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2015814 | 0.78 | ACHE (0.52) | FAAHPIK3CAGPR119CKS1BSKP1 | |
| SCHEMBL2015241 | 0.78 | CKS1B (0.49) | GPR119CKS1BSKP1SKP2 | |
| SCHEMBL2014735 | 0.78 | WNT3A (0.46) | PIK3CAGPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | NPC1 818/4885RAB9A 1129/4885FAAH 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.